ClinicalTrials.gg
Active, not recruitingNCT05633667VELOCITY-LungUpdated Jun 1, 2026

Study of Novel Treatment Combinations in Patients With Lung Cancer

A Phase 2 interventional study of Zimberelimab (ZIM) and Domvanalimab (DOM) in Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer and Resectable Non-Small-Cell Lung Cancer, sponsored by Gilead Sciences. Active, not recruiting at 89 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: Lung NeoplasmsReclassifiedWhy we changed it
Registry
Lung Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's listed conditions name Carcinoma, Non-Small-Cell Lung, a narrower term within Lung Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung — 3 open to participants now, 6 under way, 2 of them phase 3. zimberelimab · Carcinoma, Non-Small-Cell Lung.

Enrollment
3rd of 10
192 · median 152
Started
2023
with 1 other
Phase 2
4 of 10
none open now
Registered
8th of 10
by date
Lead sponsor
2 of 10
Gilead Sciences

Among the 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung, this one is the 3rd largest by enrollment, is one of 2 that started in 2023, is one of 4 in phase 2, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About zimberelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment for metastatic NSCLC. Substudy-03 will compare the different novel combinations versus standard of care in participants with resectable stage II-III NSCLC.

The primary objectives of this study are:

Substudy-01 and Substudy-02: To evaluate the objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).

Substudy-03: To evaluate the efficacy of treatment combinations based on complete pathological response (pCR) rate.

03

Conditions studied

  • Lung Cancer
  • Advanced or Metastatic Non-Small-Cell Lung Cancer
  • Resectable Non-Small-Cell Lung Cancer

Browse trials for

04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's enrollment of 192 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

All Substudies:

  • or cytologically documented non-small-cell lung cancer (NSCLC).
  • No known actionable genomic alterations for which targeted therapies are available.
  • (ECOG) performance status score of 0 or 1.
  • per .
  • Adequate hematologic and end-organ function.
  • Individuals of who engage in heterosexual intercourse must agree to use specified method(s) of .

Substudy 01: All Experimental arms

  • Stage IV NSCLC.
  • For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative.
  • status by central confirmation.
  • No prior systemic treatment for NSCLC.

Substudy 02: All Experimental arms

  • Stage IV NSCLC.
  • In individuals with nonsquamous histology and actionable EGFR, ALK, or other known genomic alterations must have received treatment with at least 1 targeted therapy to the appropriate genomic alteration.

Substudy 03: All Experimental arms

  • Previously untreated individuals with resectable (Stage II, IIIA, IIIB (T[3-4]N2) NSCLC (per American Joint Committee on Cancer (AJCC) Edition 8).
  • Planned surgery must comprise of lobectomy, sleeve lobectomy, or bi-lobectomy.
  • PD-L1 status by central confirmation.
  • For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative.

Key Exclusion Criteria:

All Substudies:

  • Mixed small-cell lung cancer and NSCLC histology.
  • Active second .
  • Active disease.
  • History of or current non-infectious pneumonitis/interstitial lung disease.
  • Active serious infection within 4 weeks prior to study treatment.

Substudy 01 and 02

  • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Received previous anticancer therapy within 4 weeks prior to enrollment.

Substudy 03: All Experimental arms

  • NSCLC previously treated with systemic therapy or radiotherapy.
  • Received prior treatment with any anti-PD-(L)-1 or other immune checkpoint inhibitors (CPIs).

Note: Other protocol defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    Substudy 01: Zimberelimab (ZIM) + Sacituzumab govitecan-hziy (SG) + Domvanalimab (DOM)

    Participants will receive ZIM, SG and DOM until disease progression (PD), unacceptable toxicity, or protocol specified discontinuation criteria are met.

    Drug: Zimberelimab (ZIM) · Drug: Domvanalimab (DOM) · Drug: Sacituzumab govitecan-hziy (SG)

  • Experimental
    Substudy 01: ZIM + DOM + Etrumadenant (ETRUMA)

    Participants will receive ZIM, DOM and ETRUMA until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met.

    Drug: Zimberelimab (ZIM) · Drug: Domvanalimab (DOM) · Drug: Etrumadenant (ETRUMA)

  • Experimental
    Substudy 01: ZIM + ETRUMA

    Participants will receive ZIM and ETRUMA until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met.

    Drug: Zimberelimab (ZIM) · Drug: Etrumadenant (ETRUMA)

  • Experimental
    Substudy 01: Zimberelimab (ZIM) + Sacituzumab govitecan-hziy (SG)

    Participants will receive ZIM and SG until disease progression (PD), unacceptable toxicity, or protocol specified discontinuation criteria are met.

    Drug: Zimberelimab (ZIM) · Drug: Sacituzumab govitecan-hziy (SG)

  • Active comparator
    Substudy 01: ZIM + Platinum Based Chemotherapy

    Expansion Stage Only: Participants will receive ZIM plus any one of the chemotherapy (choice of chemotherapy is dependent on histology). Platinum Based Chemotherapy will be cisplatin or carboplatin and pemetrexed (non-squamous histology) or carboplatin, paclitaxel and nabpaclitaxel (squamous histology).

    Drug: Zimberelimab (ZIM) · Drug: Carboplatin · Drug: Cisplatin · Drug: Pemetrexed · Drug: Paclitaxel · Drug: Nab-paclitaxel

  • Experimental
    Substudy 02: SG + ZIM + ETRUMA

    Participants will receive SG, ZIM and ETRUMA until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met.

    Drug: Zimberelimab (ZIM) · Drug: Sacituzumab govitecan-hziy (SG) · Drug: Etrumadenant (ETRUMA)

  • Active comparator
    Substudy 02: Either Docetaxel or SG (Monotherapy Only)

    Participants will receive either Docetaxel or SG until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met.

    Drug: Sacituzumab govitecan-hziy (SG) · Drug: Docetaxel

  • Experimental
    Substudy 03 - ZIM + DOM + Platinum-based Chemotherapy

    Participants will receive ZIM plus DOM and any one of the chemotherapy (choice of chemotherapy is dependent on histology). Platinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology).

    Drug: Zimberelimab (ZIM) · Drug: Domvanalimab (DOM) · Drug: Carboplatin · Drug: Pemetrexed · Drug: Paclitaxel

  • Experimental
    Substudy 03 - ZIM + Platinum-based Chemotherapy

    Participants will receive ZIM plus any one of the chemotherapy (choice of chemotherapy is dependent on histology). Platinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology).

    Drug: Zimberelimab (ZIM) · Drug: Carboplatin · Drug: Pemetrexed · Drug: Paclitaxel

  • Active comparator
    Substudy 03: Nivolumab + Platinum-based Chemotherapy

    Participants will receive nivolumab plus any one of the chemotherapy (choice of chemotherapy is dependent on histology). Platinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology).

    Drug: Carboplatin · Drug: Pemetrexed · Drug: Paclitaxel · Drug: Nivolumab

Interventions

07

What researchers measure

Primary outcomes

  1. Substudies 01 and 02: Objective Response Rate (ORR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    ORR is defined as the proportion of participants achieving a complete response (CR) or partial response (PR) as confirmed at least 4 weeks after the first detection of response.

    Time frame: Up to 5 years

  2. Substudy 03: Complete Pathological Response (pCR) Rate

    pCR is defined as the percentage of participants having an absence of residual invasive cancer in resected lung specimens and lymph nodes as assessed by local pathology review.

    Time frame: Up to 5 years

Secondary outcomes

  1. Substudies 01 and 02: Progression-free Survival (PFS) According to RECIST Version 1.1

    PFS is defined as the time from the date of randomization until disease progression (PD) or death, whichever comes first.

    Time frame: Up to 5 years

  2. Substudies 01 and 02: Duration of response (DOR) According to RECIST Version 1.1

    DOR is defined as the time from the first response (CR or PR) until the first documented PD, or death, whichever comes first.

    Time frame: Up to 5 years

  3. All Substudies: Overall survival (OS)

    OS is defined as the time from the date of randomization until death from any cause.

    Time frame: Up to 5 years

  4. Substudy 03: Event-Free Survival (EFS)

    Event-Free Survival (EFS) is defined as the time from randomization until any of the following events: any progression precluding surgery or preventing completion of surgery, progression or recurrence of disease after surgery (local or distant), as assessed by investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), or death due to any cause, whichever occurs first. Participants who do not undergo surgery for reasons other than progression will be considered to have had an event at progression or at death.

    Time frame: Up to 5 years

  5. Substudy 03: Major Pathological Response (MPR) Rate

    MPR rate is defined as the percentage of participants with ≤ 10% residual tumor in lung and lymph nodes at surgery as evaluated by local pathology review.

    Time frame: Up to 5 years

  6. All Substudies: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Related TEAEs

    Time frame: First dose date up to 24 months plus 100 days

  7. All Substudies: Percentage of Participants Experiencing Clinical Laboratory Abnormalities

    Time frame: First dose date up to 24 months plus 100 days

08

Study locations

89 sites
  • Arizona Oncology Associates,Substudy-02
    Tucson, Arizona 85711, United States
  • Fort Wayne Medical Oncology and Hematology, Inc.,Substudy-03
    Fort Wayne, Indiana 46845, United States
  • Baptist Health Lexington,Substudy-03
    Lexington, Kentucky 40503, United States
  • Washington University School of Medicine - Siteman Cancer Center,Substudy-01
    St Louis, Missouri 63110, United States
  • Washington University School of Medicine - Siteman Cancer Center,Substudy-02
    St Louis, Missouri 63110, United States
  • Washington University School of Medicine - Siteman Cancer Center,Substudy-03
    St Louis, Missouri 63110, United States
  • Washington University School of Medicine - Siteman Cancer Center
    St Louis, Missouri 63110, United States
  • Oncology Hematology Care Clinical Trials, LLC,Substudy-01
    Cincinnati, Ohio 45242, United States
  • Oncology Hematology Care Clinical Trials, LLC,Substudy-02
    Cincinnati, Ohio 45242, United States
  • Oncology Associates of Oregon, PC,Substudy-01
    Eugene, Oregon 97401, United States
  • Oncology Associates of Oregon, PC,Substudy-02
    Eugene, Oregon 97401, United States
  • Fundação Pio XII - Hospital de Amor,Substudy-01
    Barretos, 14784-400, Brazil
  • Centro Gaúcho Integrado de Oncologia Hematologia, Ensino e Pesquisa Ltda./Hospital Mãe de Deus,Substudy-03
    Porto Alegre, 90110-270, Brazil
  • Hospital Mae de Deus,Substudy-01
    Porto Alegre, 90110-270, Brazil
  • Hospital Mae de Deus
    Porto Alegre, 90110-270, Brazil
  • Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-01
    Porto Alegre, 90610001, Brazil
  • Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-03
    Porto Alegre, 90610001, Brazil
  • BP-A Beneficencia Portuguesa De Sao Paulo,Substudy-01
    São Paulo, 1509, Brazil
  • Fundação Antonio Prudente - Hospital do Câncer AC Camargo,Substudy-01
    São Paulo, 1509, Brazil
  • Fundação Antonio Prudente/A.C. Camargo Cancer Center,Substudy-03
    São Paulo, 1509, Brazil
  • Real e Benemérita Associação Portuguesa de Beneficência/Hospital Beneficência Portuguesa de São Paulo (Hospital BP),Substudy-03
    São Paulo, 1509, Brazil
  • Queen Mary Hospital,Substudy-01
    Hong Kong, 999077, Hong Kong
  • Queen Mary Hospital,Substudy-02
    Hong Kong, 999077, Hong Kong
  • Queen Elizabeth Hospital,Substudy-01
    Hong Kong, Hong Kong
  • Queen Elizabeth Hospital,Substudy-02
    Hong Kong, Hong Kong
  • Prince of Wales Hospital,Substudy-01
    New Territories, Hong Kong
  • Prince of Wales Hospital,Substudy-02
    New Territories, Hong Kong
  • Rambam Health Care Campus,Substudy-01
    Haifa, 3525408, Israel
  • Rambam Health Care Campus,Substudy-02
    Haifa, 3525408, Israel
  • Rambam Health Care Campus,Substudy-03
    Haifa, 3525408, Israel
  • Shaare Zedek Medical Center,Substudy-01
    Jerusalem, 9103102, Israel
  • Shaare Zedek Medical Center,Substudy-02
    Jerusalem, 9103102, Israel
  • Shaare Zedek Medical Center,Substudy-03
    Jerusalem, 9103102, Israel
  • Hadassah Medical Center,Substudy-01
    Jerusalem, 91120, Israel
  • Hadassah University Medical Center,Substudy-03
    Jerusalem, 91120, Israel
  • Tel Aviv Sourasky Medical Center,Substudy-01
    Tel Aviv, 64239, Israel
  • Tel Aviv Sourasky Medical Center,Substudy-02
    Tel Aviv, 64239, Israel
  • Tel-Aviv Sourasky Medical Center,Substudy-03
    Tel Aviv, 64239, Israel
  • Chungbuk National University Hospital,Substudy-01
    Cheongju-si, 28644, South Korea
  • Chungbuk National University Hospital,Substudy-02
    Cheongju-si, 28644, South Korea
  • National Cancer Center,Substudy-01
    Goyang, 410769, South Korea
  • National Cancer Center,Substudy-02
    Goyang, 410769, South Korea
  • National Cancer Center,Substudy-03
    Goyang, 410769, South Korea
  • Chonnam National University Hwasun Hospital,Substudy-01
    Gwangju, 61469, South Korea
  • Chonnam National University Hwasun Hospital,Substudy-03
    Gwangju, 61469, South Korea
  • Seoul National University Bundang Hospital,Substudy-01
    Gyeonggi-do, 463-707, South Korea
  • Seoul National University Bundang Hospital,Substudy-03
    Gyeonggi-do, 463-707, South Korea
  • Kosin University Gospel Hospital,Substudy-01
    Seogu, 49267, South Korea
  • Kosin University Gospel Hospital,Substudy-03
    Seogu, 49267, South Korea
  • Severance Hospital, Yonsei University Health System,Substudy-03
    Seoul, 03722, South Korea
  • Asan Medical Center,Substudy-02
    Seoul, 05505, South Korea
  • Asan Medical Center,Substudy-03
    Seoul, 05505, South Korea
  • Asan Medical Centre,Substudy-01
    Seoul, 05505, South Korea
  • Samsung Medical Center,Substudy-01
    Seoul, 06351, South Korea
  • Samsung Medical Center,Substudy-02
    Seoul, 06351, South Korea
  • Samsung Medical Center,Substudy-03
    Seoul, 06351, South Korea
  • Severance Hospital, Yonsei University Health System,Substudy-01
    Seoul, 120-752, South Korea
  • Severance Hospital, Yonsei University Health System,Substudy-02
    Seoul, 120-752, South Korea
  • Seoul National University,Substudy-02
    Seoul, 463-707, South Korea
  • Korea University Guro Hospital,Substudy-01
    Seoul, 8308, South Korea
  • Korea University Guro Hospital,Substudy-03
    Seoul, 8308, South Korea
  • Changhua Christian Hospital,Substudy-01
    Changhua, 500-06, Taiwan
  • Changhua Christian Hospital,Substudy-02
    Changhua, 500-06, Taiwan
  • Changhua Christian Hospital,Substudy-03
    Changhua, 500-06, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital,Substudy-01
    Kaohsiung City, 80756, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital,Substudy-02
    Kaohsiung City, 80756, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital,Substudy-03
    Kaohsiung City, 80756, Taiwan
  • Kaohsiung Chang Gung Memorial Hospital,Substudy-01
    Kaohsiung City, 83301, Taiwan
  • Kaohsiung Chang Gung Memorial Hospital,Substudy-02
    Kaohsiung City, 83301, Taiwan
  • Kaohsiung Chang Gung Memorial Hospital,Substudy-03
    Kaohsiung City, 83301, Taiwan
  • National Taiwan University Hospital,Substudy-01
    Taipei, 100, Taiwan
  • National Taiwan University Hospital,Substudy-02
    Taipei, 100, Taiwan
  • Adana City Training and Research Hospital,Substudy-01
    Adana, 01120, Turkey (Türkiye)
  • Memorial Ankara Hastanesi,Substudy-01
    Ankara, 06520, Turkey (Türkiye)
  • Memorial Ankara Hospital,Substudy-03
    Ankara, 06520, Turkey (Türkiye)
  • Medical Park Samsun,Substudy-01
    Atakum, 55200, Turkey (Türkiye)
  • Dicle University,Substudy-01
    Diyarbakır, 21100, Turkey (Türkiye)
  • Dicle University Medical Faculty,Substudy-03
    Diyarbakır, 21280, Turkey (Türkiye)
  • Necmettin Erbakan University Meram Faculty of Medicine,Substudy-01
    Konya, 42080, Turkey (Türkiye)
  • Necmettin Erbakan Universitesi,Substudy-03
    Meram Konya, 42080, Turkey (Türkiye)
  • Gazi University Medical Faculty,Substudy-01
    Yenimahalle, Turkey (Türkiye)
  • Gazi University Medical Faculty,Substudy-03
    Yenimahalle, Turkey (Türkiye)
  • Birmingham Heartlands Hospital,Substudy-03
    Birmingham, B9 5SS, United Kingdom
  • University Hospitals Birmingham NHS Trust,Substudy-01
    Birmingham, B9 5SS, United Kingdom
  • University Hospitals Birmingham NHS Trust,Substudy-02
    Birmingham, B9 5SS, United Kingdom
  • St James University Hospital,,Substudy-01
    Leeds, LS9 7TF, United Kingdom
  • St. Bartholomew's Hospital,Substudy-01
    London, E1 1BB, United Kingdom
  • St. Bartholomew's Hospital,Substudy-02
    London, E1 1BB, United Kingdom
  • St. Bartholomew's Hospital,Substudy-03
    London, E1 1BB, United Kingdom
09

References and documents

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Sep 2029, 78 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 78 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2022
First posted
Dec 1, 2022
StartActual
Mar 16, 2023
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05633667
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Dec 1, 2022
Start date
Mar 16, 2023
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Jun 1, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zimberelimab · Domvanalimab · Sacituzumab govitecan · AB928 · Carboplatin · Pemetrexed · Paclitaxel

Start the discussion